ArticlePediatric surgery international2026
Post-Operative Ketorolac in Children After Crohn's Ileocecectomy.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate complications and flare rates in children with Crohn's disease who received ketorolac following ileocecectomy.
methodsElectronic medical record data of patients < 18 years with Crohn's disease undergoing ileocecectomy at a single institution from 1/1/2013-9/1/2023 were retrospectively reviewed. Demographics, operative course, 30-day complications, and Crohn's flares, small bowel obstructions (SBO), and strictures within two years were collected. Patients who received post-operative ketorolac were compared to those who did not.
results191 patients met criteria. 169(88.5%) received ketorolac and 22(11.5%) did not. Median age was 15.9[14.2, 17.8] years. Age, sex, pre-operative steroid use, biologic use, and labs were similar between groups. The majority (97.9%) were laparoscopic-assisted. Post-operatively, ketorolac-exposed patients required significantly less opioids (17.0[3.9, 35.2] morphine milli-equivalents vs. 39.7[8.4, 58.7], p = 0.048). Length of stay, days to first flatus, and days to ambulation were similar. There were 18(9.4%) 30-day complications, with no differences between groups. There was no difference in the number of Crohn's flares (3(1.8%) vs. 1(4.5%), p = 0.39), SBOs (8(4.7%) vs. 0(0%), p = 0.6), or strictures (1(0.6%) vs. 0(0%), p > 0.99).
conclusionIn this single-institution analysis, no association between post-operative ketorolac and Crohn's flares was detected, though further study is required. Patients who receive ketorolac may benefit from decreased opioid consumption.
Indexed as
Identifiers
42832108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.